Notch signaling

(redirected from Notch pathway)

Notch signaling

[′näch ‚sig·nəl·iŋ]
(embryology)
An evolutionarily conserved developmental pathway utilized during the differentiation of a plethora of tissue types, in organisms as diverse as nematodes and humans.
References in periodicals archive ?
There are today 309 companies plus partners developing 369 Notch pathway targeting drugs in 1485 developmental projects in cancer.
In their latest work, the investigators found that blocking the Notch pathway increases the formation of new hair cells not from remaining hair cells but from certain nearby supporting cells that express a protein called Lgr5.
Novel compounds such as inhibitors of the sonic hedgehog or the Notch pathway are under clinical investigation.
21) Apparently, a cautious evaluation should be performed on a cancer system in which the roles of the Notch pathway remain largely unknown.
They also observed upregulation of the Notch pathway in breast cancer stem cells via upregulation of Notch receptor ligands.
Other topics include the immunology of multiple sclerosis, macrophage receptors and immune recognition, immune responses to the blood stages of malaria, maintenance of serum antibody levels, B cell signaling and tumorigenesis, and regulation of lymphoid development and function by the notch pathway.
Ian Flinn of SCRI, who treated the first patient with OMP-52M51, "It is exciting to bring a novel antibody such as OMP-52M51 that targets the Notch pathway, a key cancer stem cell pathway, into the clinic.
We uncovered a novel mechanism by which the Notch pathway could contribute to RA," said Xiaoyu Hu, M.
from one of the groups that has pioneered breast cancer stem cell research, describe the dysregulated pathways, such as the Notch signalling pathway, and the connection between Notch pathway activation of breast cancer stem cells, stem cell self-renewal pathways and how this might lead to novel therapeutic targets in both pre-invasive and invasive breast cancer.
In addition, the company presented a poster (Abstract #314, Poster #64) describing the results of a comprehensive biomarker analysis in the Anti-Notch2/3 Phase 1 study, which demonstrated pharmacodynamic (PD) modulation of the Notch pathway in patients with advanced solid tumors.